Responses
Immunotherapy biomarkers
Original research
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
